Key facts
- This page summarizes Ronald Kirk Huntsman's Form 4 filing for Vivos Therapeutics, Inc. (VVOS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Nov 2024, 16:47.
Ronald Kirk Huntsman - 26 Nov 2024 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- VVOS
- Reported as of
- 26 Nov 2024
- Net transaction value
- +$832,711
- SEC form
- 4
- Accepted by SEC
- 27 Nov 2024, 16:47:13 UTC
- Prior SEC filing
- 28 Jun 2024
- Next SEC filing
- 18 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bradford K. Amman as attorney-in-fact for Ronald Kirk Huntsman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ronald Kirk Huntsman filed Form 4 for Vivos Therapeutics, Inc. (VVOS) on 27 Nov 2024.
Change
- Previous filing in this sequence was filed on 28 Jun 2024.
- Current net transaction value: +$832,711.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VVOS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,461
- Date
- 26 Nov 2024
- Ownership
- Direct
VVOS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 69,600
- Date
- 26 Nov 2024
- Ownership
- See footnote
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VVOS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $832,711
- Shares
- +315,421
- Change %
- +639%
- Price
- $2.64
- Shares after
- 364,755
- Date
- 26 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 315,421
- Exercise price
- $2.64
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.
Footnote F2
On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027.